Circadian Technologies managing director boosts take with on market purchases

Circadian Technologies (ASX: CIR) managing direct Robert Klupacs has increased his direct stake in the company with an on-market purchase.

Klupacs purchased 46,000 shares for a consideration of $25,740, which equates to an average entry price of $0.56.

Klupacs now holds almost 244,000 shares in the company, and also has three lines of around half a million unlisted employee options.

Circadian - the year ahead

In the Circadian preliminary report released last week, the company outlined the year ahead, with key events including:

- IND filing in respect of the VGX-100 with the US FDA and subsequent commencement of clinical trials;
- Generation of additional data in animal models on corneal diseases to support development of VGX-100 in corneal disease settings;
- Launch of CUP diagnostic test by Healthscope;
- Development of additional clinical diagnostic tests for the measurement of VEGF-C, VEGF-D and/or VEGFR-3 in patient tissue as diagnostic assays in oncology; and
- Continued expansion of the marketing of our VEGF-D based diagnostic test for LAM, outside of the USA.

Originally published at: http://www.proactiveinvestors.com.au/companies/news/19096/circadian-technologies-managing-director-boosts-take-with-on-market-purchases-19096.html